In December 2022, a mixture of cells that form the outer blood-retina barrier eye tissue, which supports light-sensing photoreceptors of the retina, was printed by The National Eye Institute (NEI), part of the National Institutes of Health. This is an approach through which scientists can now study retinal degenerative diseases such as age-related macular degeneration with patient-specific tissues that are potentially unlimited in supply (AMD).
The Indian Institute of Science (IISc) in September 2022 announced its collaboration with CELLINK, a bioprinting solutions provider based in Sweden, to give two or three bioprinters to the Centre of Excellence (CoE), each using different printing technology at its own cost. The Indian Institute of Science will open its first dedicated center for 3D bioprinting technology in about two months’ time (IISc). IISc has plans to establish a Center of Excellence on 3D Bioprinting within its Centre for Biosystems Science and Engineering (BSSE). This CoE also aims to develop this discipline by serving as a referral point for researchers, biopharma firms, hospitals, and other entities.
In June 2022, REGEMAT 3D announced that it had partnered with Humabiologics to increase demand and expanding life science customer base towards bio-fabrication industry partners and academic institutions across Europe’s market leaders on Bioprinting and drug testing.
BIOSYSTEMS CO.’S introduced BIO CELLX- this is a revolutionary technology that automates 3D cell cultivation procedures using pre-validated methods
June 2021 saw the signing by CollPlant Biomaterials Limited (Israel) & 3d Printers, Inc. (US) of a co-development agreement for such an implant-assisted surgical procedure utilizing implantable regenerating tissue in combination with an implant.
September 2022 – CELLINK, a Swedish bioprinting solutions company, entered into an agreement with the Indian Institute of Science (IISc) to offer three bioprinters for the Centre of Excellence (CoE), each having different printing technology at the expense of CELLINK. By this time around, India hopes to be home to its first-ever exclusive center for 3D bioprinting technology at the Indian Institute of Science (IISc). IISc will establish its CoE on 3D Bioprinting within the Centre for Biosystems Science and Engineering (BSSE). The CoE intends to promote growth in the field by being an information hub for researchers, bio-pharma industry players, and hospitals, among others.
REGEMAT 3D announced a partnership with Humabiologics in June 2022 as a response to increasing demand and a growing life science customer base from industrial partners and academic institutions in Europe’s leading bioprinting and drug testing market.
3D Bioprinting Market Trends
- Growing high demand for transplantable tissues and organs to boost market growth
Globally, there is a massive demand for vital body parts for transplantation. Even worse, there is a significant discrepancy between the supply and demand of organs and tissues. The heart, kidneys, lungs, liver, pancreas, and intestines are just a few organs required for transplantation.
Similarly, there is a tremendous demand for bone, skin, blood vessels, heart valves, and cornea transplants. Although there is a growing need for organs and tissues, organ donation rates remain the same. The increasing number of patients on the transplant waiting list as a result of the unavailability of these parts for transplantation is a significant problem for healthcare organizations and providers. Since researchers are utilizing new technologies for safety testing in patients after preclinical trials are finished, the coronavirus pandemic has also sped up the development of medicine and vaccine testing. The medical community is also experiencing a respirator and ventilator shortage due to the rising number of COVID-19 cases. To address the lack of this equipment, 3D bioprinting technology assists in producing respirators and ventilators. Companies across the world are soaring high on innovation and creativity that will help in coming up with regenerative medicine along with their concept solutions related to tissue engineering, stem cell therapies, alongside drug therapies.
A respiratory epithelium model was recently produced by the 3D bioprinting business CLECELL combining existing bioprinting technologies and their 3D printer, the U-FAB. A type of tissue called respiratory epithelium lines most of the respiratory tract. This epithelium blocks pathogens and foreign substances. Consequently, the market for 3D bioprinting will be expected to expand due to rising demand for this respiratory epithelium model. Therefore, the condition has recently enhanced the 3D Bioprinting market CAGR globally.
However, the growth of public and private funding for research efforts in bioprinting is another factor driving the market revenue of the 3D Bioprinting.
3D Bioprinting Market Segment Insights
3D Bioprinting Insights
Based on technology, the market segments of 3D Bioprinting includes micro extrusion bioprinting, inkjet 3D bioprinting, laser-assisted bioprinting, and magnetic 3D bioprinting. The Inkjet 3D Bioprinting segment held the majority share in 2022, contributing to around ~40% of the 3D Bioprinting market revenue. One of the driving forces behind the development of this market is the extensive usage of inkjet printing in the healthcare sector. This study specifically addresses the issues of biochemical regeneration, medication delivery costs, and inkjet printing as a bio-applicable technique. This market segment is anticipated to expand significantly due to its increased durability and rising demand.
3D Bioprinting Insights
Based on Material, the global 3D Bioprinting market segmentation includes living cells, hydrogels, and extracellular matrices. The Living Cells segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. because investments in stem cells and regenerative medicine are rising along with the utilization of living cells in these fields. For instance, thanks to the technology platform developed by 3DBio Therapeutics, a startup company started by a Cornellian; people have received 3D- bio-printed ear implants made from patients' live cells in a first-of-its-kind clinical investigation. Hence, rising applications of Living Cells material implants for 3D bioprinting positively impact market growth.
3D Bioprinting Application Insights
The market data of 3D Bioprinting has been bifurcated by application into research applications and clinical applications. The clinical applications segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Skin, bone and cartilage, blood vessels, and other clinical applications make up the clinical applications sector. Throughout the forecast period, the clinical applications segment is anticipated to dominate the global market regarding revenue share. Creating skin tissues that are not only directly implantable but also capable of stimulating skin regeneration and scar reduction in trauma care has been the focus of research into a novel, portable 3D bioprinting process.
Figure 2: 3D Bioprinting Market, by Application, 2022 & 2032 (USD billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Research applications were the fastest-growing segment due to the increasing successes of scholars and business players. Bioprinting can, for instance, reproduce a complicated cancer microenvironment by precisely arranging numerous cell types and even microcapillaries. This approach develops new methods for producing prescription drugs by assisting researchers in understanding the growth and spread of cancer.
3D Bioprinting End User Insights
Based on End Users, the global 3D Bioprinting industry has been segmented into Pharmaceutical & and biotechnology companies, Research Organizations & Academic Institutes. Research Organizations & Academic Institutes held the most significant segment share in 2022; this is because stem cell research is moving forward quickly, expenditures are expanding to speed up Research & Development (R&D) efforts, and demand for regenerative medicine is rising as a result of the high frequency of chronic diseases.
The third fastest-growing segment in the 3D Bioprinting industry is pharmaceutical & biotechnology companies. Due to patients' increased reliance on technology, the development of tailored medicines, and the creation of bio-drugs using 3D bioprinting technology. For instance, Poietis and Servier, a pharmaceutical company, worked together to develop a 4D bioprinted liver model that was also better than current methods at predicting medication and liver damage.
3D Bioprinting Regional Insights
The analysis offers market insights for North America, Europe, Asia-Pacific, and the rest of the world, by region. The market for 3D bioprinting in North America reached USD 0.87 billion in 2022 and is anticipated to increase at a substantial CAGR throughout the research period. Throughout the projection period, the market would rise due to the growing adoption of IT in the healthcare sector. Around 23,369,732 active COVID-19 cases were registered in the United States alone up until January 13th, 2021, according to the Worldometer Report 2021. Over 50 vaccine candidates are now being tested. The government is investing more in research and development to produce a vaccination for this illnessa.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: 3D Bioprinting Market Share By Region 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's 3D Bioprinting market accounts for the second-largest market share due to increasing R&D activities, growing demand for organ transplants, and increasing initiatives by market players to expand their presence in this region. Further, the German market of 3D Bioprinting held the largest market share, and the UK market of 3D Bioprinting was the fastest-growing market in the European region.
The Asia-Pacific market of 3D Bioprinting is expected to grow at the fastest CAGR from 2024 to 2032. due to the size of its consumer base, the growth of this field's R&D, government backing, and tax advantages. Significant developments in this field have been achieved by Chinese researchers, including the liquid-in-liquid printing technique, which combines liquid polymers to create a stable membrane. They claim that the resulting fluid structures can hold their shape for up to 10 days before merging. Moreover, China's market of 3D Bioprinting had the largest market share, and India's 3D Bioprinting market was the fastest-growing market in the Asia-Pacific region.
3D Bioprinting Key Market Players & Competitive Insights
Major industry companies are investing a lot of money in R&D to expand their product offerings, which will spur further market growth in the 3D bioprinting. With key developments changes like new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market participants are also undertaking various strategic activities to expand their global presence. To grow and thrive in an environment where competition is fierce, and the market is growing, competitors in the 3D bioprinting industry must provide affordable products.
Manufacturing locally to cut operational costs is one of the leading business tactics used by manufacturers in the worldwide 3D Bioprinting industry to benefit customers and grow the market sector.In recent years, 3D Bioprinting industry has provided medicine with some of the most significant benefits. The 3D Bioprinting market major player such as EnvisionTEC, CELLINK and Others are working to expand the market demand by investing in research and development activities.
Using seven different process technologies, the privately held business EnvisionTEC creates, produces, and distributes more than 40 variants of desktop and commercial 3D printers that create items from digital design files. In September 2021, To minimize entry barriers for businesses wishing to embrace 3D printing for making molds for low volumes and more commercially, EnvisionTEC and Covestro announced their partnership on material+printer solutions.
Also, A bioconvergence firm called Bico Group creates and offers tools and services to advance biological research. In August 2022, Indian Institute of Science (IISC) and CELLINK, a world leader in 3D bioprinter development, announced their collaboration to build a 3D bioprinting Center of Excellence in Bengaluru, India. Researchers will have access to 3D bioprinting systems through the Centre of Excellence (CoE), housed in the Centre for BioSystems Science and Engineering (BSSE) at IISc. This will enable them to advance their projects through targeted applications to enhance medical outcomes.
Key Companies in the 3D Bioprinting market includes
- Organovo Holdings, Inc. (US)
- ROKIT Healthcare (South Korea)
- Cyfuse Biomedical K.K. (Japan)
- CELLINK (Sweden)
- EnvisionTEC GmbH (Germany)
- Allevi Inc. (US)
- Aspect Biosystems Ltd. (Canada)), among Others
3D Bioprinting Industry Developments
November 2023: Stratasys (Israel) introduced the F3300 Fused Deposition Modelling (FDM) 3D printing technology. The F3300 product will be more cost-effective than current Stratasys FDM solutions, with faster extrusion, autocalibration, and gantry speeds.
August 2023: Cellink (Sweden) unveiled the Bio X3 bioprinter, a multipurpose bioprinter that can print a variety of materials, such as cells, hydrogels, and biomolecules. Cellink's Bio X is a multipurpose, standalone 3D bioprinter with three replaceable printheads that may be used with a variety of bioinks and biomaterials.
3D Bioprinting Market Segmentation
3D Bioprinting Outlook
- Microextrusion Bioprinting
- Inkjet 3D Bioprinting
- Laser-assisted Bioprinting
- Magnetic 3D Bioprinting
3D Bioprinting Outlook
- Living Cells
- Hydrogels
- Extracellular Matrices
3D Bioprinting Application Outlook
- Research Applications
- Clinical Applications
3D Bioprinting End User Outlook
- Pharmaceutical & Biotechnology Companies
- Research Organizations & Academic Institutes
3D Bioprinting Regional Outlook
-
North America
-
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
-
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
-
Rest of the World
- Middle East
- Africa
- Latin America
